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Claudinsarethemajorcomponentofthetightjunctionsinepithelialcellsandassuchplayakeyroleinthepolarizedlocationofion
channels, receptors, and enzymes to the diﬀerent membrane domains. In that regard, claudins are necessary for the harmonious
development of a functional epithelium. Moreover, defective tight junctions have been associated with the development of
neoplastic phenotype in epithelial cells. Breakdown of cell-cell interactions and deregulation of the expression of junctional
proteins are therefore believed to be key steps in invasion and metastasis. Several studies suggest that the claudins are major
participants in breast tumorigenesis. In this paper, we discuss recent advances in our understanding of the potential role of
claudin 1 in breast cancer. We also discuss the signiﬁcance of a subset of estrogen receptor negative breast cancers which express
“high” levels of the claudin 1 protein. We propose that claudin 1 functions both as a tumor suppressor as well as a tumor
enhancer/facilitator in breast cancer.
1. Breast Cancer
Breast cancer remains one of the most commonly diagnosed
cancers among women in North America [1]. Based on
molecular, epidemiological, and histological observations, a
morphological progression model for breast cancer has been
assembledwithinthelastdecade[2–4].Thisproposedmodel
(Figure 1) outlines a continuum of lesions describing a step-
wiseprogressionofbreastcancer,fromepithelialhyperplasia,
through atypical hyperplasia and ductal carcinoma in situ,
to invasive carcinoma and eventually metastatic disease [2–
4]. Despite many advances in the diagnosis and treatment
of breast cancer, metastasis remains an insurmountable
challenge. About 40% of women currently fail primary
management strategies for early breast cancer and ultimately
succumb to the disease.
The complex nature of the disease presentation and
the limitations in identifying clinically relevant subsets of
patients create major diﬃculties for current breast cancer
diagnosticandtherapeuticstrategies.Agrowingunderstand-
ing of the heterogeneous nature of this disease has stemmed
primarily from cDNA microarray and immunohistochemi-
cal studies, which have led to a redeﬁnition of breast cancer
subsets [5–10]. To date, 5 distinct breast cancer categories
havebeenidentiﬁed(Table 1,[5–10])basedonER/PRstatus,
Her2, CK5/6, and EGFR expression. Therapeutically, these
subtypes have been shown to display a wide variety of
responses to diﬀerent treatments [6, 11, 12] .T h el u m i n a lA
subtype (Table 1), which is more sensitive to hormones, has
the most favorable outcome whereas the Her2 and the basal
subtypes, which are not sensitive to hormones, are more
aggressive, demonstrate the worst prognosis, and have fewer
therapeutic options [13–15]. Evidently, the further identi-
ﬁcation of diﬀerent subtypes of breast cancer will provide
more therapeutic opportunities to match the characteristics
of individual breast cancer patients, enhancing our ability to
begin to oﬀer individualized treatment to patients.
Two hypothetical models have been proposed to explain
the evolution of breast cancer subtypes [18]. In the ﬁrst
model, the linear model, the cell of origin is the same
for diﬀerent tumor subtypes (and thus, tumor subtype is
determined by acquired genetic and epigenetic events). In2 Journal of Biomedicine and Biotechnology
Normal
Proliferative
disease
without
atypia
Atypical
ductal
hyperplasia
Ductal
carcinoma
in situ
Invasive
ductal
carcinoma
Basement membrane
Luminal epithelial cells
Myoepithelial cells
Figure1:Hypotheticalmodelofbreasttumorigenesisandprogression.Thestepwiseprogressionofbreastcancerisdescribedasacontinuum
of lesions from epithelial hyperplasia to invasive carcinoma and eventually metastasis.
Table 1: The ﬁve distinct subtypes of breast cancer and their corresponding phenotypes.
Subtypes Phenotype BC Cell Lines References
Luminal A ER+ve and/or PR+ve, Her2−ve MCF7, T47D, ZR75-1 [3, 6, 9, 16]
Luminal B ER+ve and/or PR+ve, Her2+ve MDA361, BT474, ZR75-30 [3, 6, 9, 16]
Her2 overexpressing ER−ve, PR−ve, Her2+ve HCC202, HCC1419,
HCC1569, HCC1954 [3, 6, 16]
Basal-like ER−ve, PR−ve, Her2−ve, CK5,6+ve
and/or EGFR+ve BT20, MDA231, MDA468 [3, 6–8, 16, 17]
Normal-like
not clearly deﬁned, similar to normal
epithelia, displays putative-initiating stem
cell phenotype
N/A [3, 6, 10]
BC: breast cancer; ER: estrogen receptor; PR: progesterone receptor; Her2: human epidermal growth factor receptor 2; CK5,6: cytokeratin 5, 6; EGFR:
epidermal growth factor receptor; +ve: positive; −ve: negative; N/A: not available.
the second model, the nonlinear model, the cell of origin is
diﬀerent (presumably a stem cell or a progenitor cell) for the
diﬀerent subtypes. Recent work by Jeselsohn et al. [19]h a s
provided evidence to suggest that there are two populations
of progenitor cells, one giving rise to the luminal-like breast
cancers and the other to the basal-like breast cancers.
2. EpithelialMesenchymal Transition(EMT)
The acquisition of the invasive phenotype is thought to mark
the most signiﬁcant change in breast cancer biology as it rep-
resents the ﬁrst step towards the development of metastatic
disease. As cells convert from the noninvasive to the invasive
phenotype, they become anchorage independent and exhibit
enhanced motility as well as increased aggressiveness, a pro-
cess referred to as epithelial-mesenchymal transition (EMT).
During this transition, epithelial cells acquire a mese-
nchymal-like phenotype via disruption of intercellular adhe-
sion and enhanced motility (for review see [20]). It is
believed that cells switch from a keratin (epithelial) rich net-
work to a vimentin (mesenchymal) rich network to facilitate
their motility [20, 21]. As for mesenchymal cells, in contrast
to epithelial cells, they can individually migrate, penetrate
into surrounding tissues, and spread to distant sites [20, 22,
23]. The breakdown of cell-cell interactions and the dereg-
ulated expression of the junctional proteins are therefore
believed to be key steps in invasion and metastasis [24, 25].
3. Tight Junctions
Tight junctions are the most apical of intercellular junctions
and appear as a network of continuous and anastomosing
ﬁlaments on the protoplasmic face of the plasma membrane
[27]( Figure 2). They contribute to the transepithelial barrier
that controls the transport of ions and small molecules
through the paracellular pathway, a property referred to
as the “barrier” function [28, 29]. Tight junctions are
also crucial for the organization of epithelial cell polarity,Journal of Biomedicine and Biotechnology 3
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Figure 2: Tight Junctions. Tight junctions are the most apical intercellular junctions in epithelial cells. The major molecular components
of the tight junctions are the claudins, occludin, and the junctional adhesion molecule (JAM). Tight junction proteins in conjunction with
adheren junction proteins (cadherins, catenins) form epithelial cell junctional complexes [26]. The gap junction is located basal to the
adheren junction.
separating the plasma membrane into apical and basolateral
domains [30–35]. As well, they are also critical for the
polarized location of ion channels, receptors, and enzymes
to the membrane domains necessary for structurally and
functionally developed epithelia, a function referred to as
the “fence” function [28, 36]. Tight junctions are there-
fore essential for the tight sealing of cellular sheets and
maintaining homeostasis [35]. Aside from maintaining cell
polarity and paracellular functions, tight junction proteins
are involved in recruiting signaling proteins [37]. Primarily,
three types of integral membrane proteins constitute the
tight junctions (Figure 2); the claudins, occludin and the
junctional adhesion molecule(s), with the claudins and
occludin being the two main molecular components in
forming the tight junction strand. The junctional adhesion
molecule is believed to function as the initial spatial cue
for tight junction formation [32]. In conjunction with the
adheren junction proteins, which are responsible for the
mechanicaladhesionbetweenadjacentcellsandthestabiliza-
tion of the whole multicellular architecture, they constitute
the apical junctional complex in epithelial tissue [33, 38].
4. Tight Junction Proteinsand Tumorigenesis
A strong association between tight junction proteins and
cancer development has been established. Alterations in the
structure and function of tight junctions have indeed been
reported in adenocarcinomas of various organs [39–41]. An
absence of tight junctions or defective tight junctions has
also been associated with the development of the neoplastic
phenotype in epithelial cells [29, 33, 42]. Such observations
are consistent with the accepted idea that the disruption
of tight junctions leads to loss of cohesion, invasiveness,
and the lack of diﬀerentiation, thereby promoting tumori-
genesis. Currently, most knowledge regarding the role of
junctional proteins in cancer, and more speciﬁcally breast
cancer, has stemmed from studies on the major adheren
junction protein, E cadherin (for review see [20, 33]). The
downregulation of E cadherin is believed to be an important
molecular event during epithelial-mesenchymal transition
[20]. In contrast to E cadherin, the role of the tight junction
proteins is not well understood in breast cancer.
4.1. The Claudins. The claudins are the major component
of the tight junction, and 24 members of this family of
proteins have been identiﬁed to date [26, 27]. They are
small proteins ranging in size from 22 to 27kD and are
encoded by at least 17 human genes (Table 2), located on
12 diﬀerent chromosomes [43, 44]. The distribution of
the loci for the claudin genes among so many diﬀerent
chromosomes is interesting as generally many gene families
have most, if not all of their members located on one
chromosome [45, 46]. The wide distribution may reﬂect
the multifunctional characteristics of these proteins. Three
claudin gene clusters are readily apparent on chromosome
3 (3q28), 4 (4q35.1), and 7 (7q11.23) and it is very likely
thatmemberswithintheseclustersmayhavesimilarfunction
and tissue speciﬁcity [47]. Aside from these three claudin
gene clusters, there appears to be no other obvious pattern
(Table 2). It is possible that the expansion of the claudin
gene family in humans may have allowed for the acquisition
of novel functions during evolution, as postulated for this
gene family in teleost ﬁsh [48]. The claudins share a
common transmembrane topology; each family member
is predicted to possess four transmembrane domains with
intracellular amino and carboxyl-termini in the cytoplasm4 Journal of Biomedicine and Biotechnology
Table 2: Chromosomal locations of the 24 members of the claudin gene family and examples of their tissue-speciﬁc gene expression in
normal and neoplastic tissues. Homologues for all members of this family (except CLDN21) are also found in chimpanzee, mouse, dog, rat,
chicken, and ﬁsh.
Gene Human Chromosomal Location
Tissue Expression1
Breast Prostate Lung Liver
Normal Cancer Normal Cancer Normal Cancer Normal Cancer
CLDN1 3q28-q29 8.7 2.4 1.5 0.8 5.0 10.1 21.1 14.9
CLDN2 Xq22.3-q23 0.5 1.1 0.7 1.2 1.3 2.5 0.0 0.0
CLDN3 7q11.23 29.2 85.1 7.5 37.8 1.3 47.8 6.0 7.4
CLDN4 7q11.23 134.5 192.8 6.0 27.2 10.0 70.4 0.0 14.9
CLDN5 22q11.21 8.7 3.2 0.7 0.4 7.5 2.5 0.0 0.0
CLDN6 16p13.3 0.3 0.5 0.0 0.0 0.0 0.0 0.0 0.0
CLDN7 17p13 20.4 13.4 24.0 9.8 7.5 25.1 0.0 37.2
CLDN8 21q22.11 0.9 0.4 0.7 0.4 0.0 0.0 0.0 0.0
CLDN9 16p13.3 0.3 1.7 0.0 0.0 0.0 0.0 0.0 0.0
CLDN10 13q31-q34 0.3 0.1 0.7 0.4 0.0 1.3 0.0 0.9
CLDN11 3q26.2-q26.3 1.7 1.0 1.5 0.8 0.0 0.0 0.0 2.8
CLDN12 7q21 12.4 9.3 3.7 4.5 15.0 1.3 15.1 6.5
CLDN13∗ N/A N/A N/A N/A N/A N/A N/A N/A N/A
CLDN14 21q22.3 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0
CLDN15 7q11.22 1.9 2.5 0.7 2.8 0.0 7.5 0.0 1.9
CLDN16 3q28 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0
CLDN17 21q22.11 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0
CLDN18 3q22.3 0.0 0.0 0.0 0.0 2.5 1.3 0.0 0.0
CLDN19 1p34.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0
CLDN20 6q25 0.2 0.7 0.0 3.3 0.0 1.3 0.0 1.9
CLDN21 4q35.1 N/A N/A N/A N/A N/A N/A N/A N/A
CLDN22 4q35.1 2.6 5.5 7.5 6.5 3.8 5.0 9.0 6.5
CLDN23 8p23.1 2.1 5.7 14.2 23.2 11.3 8.8 3.0 11.2
CLDN24 4q35.1 N/A N/A N/A N/A N/A N/A N/A N/A
1Relative gene expression (SAGE data) derived from the Cancer Genome Anatomy Project (CGAP [50]).
∗Mouse only; N/A: not available; 0.0: not detected
Numbers in columns indicate the number of tags/200,000 for each tissue/histology.
and two extracellular loops [33, 49]. The expression pattern
of the claudin proteins is tissue speciﬁc [33]; however, most
tissues express multiple claudins that can interact in either a
homotypic or heterotypic fashion to form the tight junction
strand [33, 50]. The exact combination of the claudin
proteins within a given tissue determines the selectivity,
strength and tightness of the tight junction [33, 51].
To date, only a few studies have addressed the role of
claudins in breast cancer and ﬁndings on their function
remain controversial [47, 52, 53]. In several cancers, includ-
ing breast cancer, altered protein expression of some claudin
familymembershasbeendemonstrated(forreviewsee[33]).
For example, protein expression of claudin 3 and 4 has
been shown to be upregulated in invasive breast cancer [47]
whereas, also in invasive breast cancer, the expression of the
claudin 1 and 7 proteins were downregulated [47, 53, 54].
4.2. Claudin 1. Knockout mice experiments have estab-
lished that the tight junction protein claudin 1, and not
occludin, forms the backbone of the tight junction strand
and is crucial for the epidermal barrier function [35, 55].
Expression of claudin 1 has been examined in a number
of cancers (for review see [56]). Both an increase and a
decrease in claudin 1 protein expression have been shown
to be associated with tumorigenesis. In some cancers,
including prostate [57], breast [47, 58], and melanocytic
neoplasia [59], loss of claudin 1 has been associated with
cancer progression and invasion, and the acquisition of
the metastatic phenotype. In esophageal squamous cell
carcinoma [60] decreased expression of claudin 1 correlated
with recurrence and shorter disease free survival, whereas in
lung cancer, claudin 1 was shown to suppress the expression
of invasion/metastasis enhancers and increase expression of
cancer invasion/metastasis suppressors, thereby providing
supporting evidence to suggest that it functions as a cancer
invasion/metastasis suppressor [61]. Conversely, in other
cancers, such as papillary thyroid [62]o r a ls q u a m o u sc e l l
carcinoma [63], ovarian [64], colon [65, 66], melanoma
[67], and gastric [68], overexpression of claudin 1 has been
associated with aggressiveness and the increased malignant
phenotype. Further, functional studies have shown that
claudin 1 could recruit and promote the activation of theJournal of Biomedicine and Biotechnology 5
metalloproteinase MMP-2 [63, 69]a n dl e a dt oam o r e
aggressive phenotype in oral and ovarian cancer.
5.Claudin1inNormalBreast
andBreast Cancer
In the normal mammary gland, tight junction proteins have
mainly been investigated in relation to lactogenesis [32].
Previous work from our laboratory has identiﬁed claudin 1
as a highly upregulated gene during early mammary gland
involution [70], and its expression was found to be tightly
regulated during diﬀerent stages of normal mouse gland
development [71]. Recently, there has been an increased
interest in the potential role of claudin 1 in breast cancer.
Although studies are still relatively limited, there are a
few critical reports which demonstrate a clear association
between claudin 1 expression and breast cancer progression.
The majority of studies point to a downregulation or
complete loss of claudin 1 expression in malignant invasive
human breast cancers [47, 53], and in some human breast
cancer cell lines [72]. A correlation between claudin 1
down regulation and disease recurrence was also recently
reported [73]. Additionally, functional studies also suggest
that claudin 1 may be a key player in breast tumorigenesis.
A down regulation of claudin 1 gene expression was shown
to lead to neoplastic transformation of breast epithelial cells
[74]. As well, the re-expression of claudin 1 alone was shown
to be suﬃcient to induce apoptosis in a human breast cancer
cell line [75]. It has also been suggested that claudin 1 alone
might be suﬃcient to exert a tight junction-mediated gate
function in metastatic tumor cells even in the absence of
other tight junction-associated proteins [52]. In addition,
subcellular localization of claudin 1 has been shown (by us
[76]andothers[47,76,77])tobedisruptedininvasivebreast
cancer leading to a detection of this protein in the cytoplasm.
Interestingly, an association between claudin 1 and epithelial
mesenchymal transition has recently been established. As
with E cadherin [78, 79] the transcription factors, slug and
snail, key markers of epithelial mesenchymal transition, were
shown to bind to the claudin 1 promoter resulting in the
repression of its activation [80].
Additional work from our laboratory has also provided
evidence to show that claudin 1 expression in breast cancer
is even more complex than originally thought. Using tissue
microarray strategies, we showed that in a cohort of human
invasive breast cancers exhibiting mixed pathological lesions
(340 biopsies, the largestexamined to date), only a small per-
centage of tumors express claudin 1 protein. The frequency
of claudin 1 positive tumors was signiﬁcantly lower than the
frequency of tumors observed as positive for claudin 3 and 4,
two family members previously shown to be overexpressed
in invasive human breast cancer [47].
SinceERstatusisoftenconsideredanimportantclassiﬁer
of breast cancers (Table 1), we wanted to determine whether
therewasanyassociationbetweenestrogen/estrogenreceptor
and claudin 1. We showed that in ER+ve breast cancers (189
biopsies), a signiﬁcantly small number of tumors (5%) were
positive for claudin 1 expression, while in the ER−ve tumors
(151 biopsies), the frequency of positive tumor staining for
claudin 1 was signiﬁcantly higher (39%) [76]. A positive
association was also found with EGFR, a marker of poor
prognosis. Surprisingly, a signiﬁcant correlation was also
foundwithclaudin1andmarkersofthebasal-likesubtypeof
breastcancers[76,81],anaggressivesubtypeofbreastcancer
associated with the worst prognosis and reduced patient
survival. We also demonstrated for the ﬁrst time that in the
estrogen receptor positive (ER+ve) human cell line, MCF7,
that claudin 1 expression was down regulated by estrogen in
vitro (unpublished data).
6. Is Claudin1 MuchMore than a Tumor
Suppressor in Breast Tumorigenesis?
Both an over and an underexpression of claudin 1 have
been observed in diﬀerent types of cancers [57, 59, 62, 63,
65–67, 69], outlining the complexity of its potential role
in carcinogenesis. In breast cancer, the majority of studies
published to date, though limited in numbers, show that
partial or total loss of claudin 1 expression correlates with
increased malignant potential and invasiveness and with
recurrence of disease [47, 73]. As well, the re-expression
of claudin 1 in breast cancer cells was demonstrated to
induce apoptosis [75]. Additionally, our tissue microarray
studies showed that a signiﬁcantly low frequency of human
invasive breast cancers was positive for claudin 1 expression
[76]. Altogether, these studies provide supporting evidence
to suggest that claudin 1 functions as a tumor suppressor in
breast tumorigenesis.
Paradoxically, our laboratory has also provided evidence
to suggest that the role of claudin 1 in breast cancer may
be much more than a tumor suppressor. We showed in
our TMA studies that the frequency of claudin 1 positive
tumors was signiﬁcantly higher in ER−ve breast cancers
than in ER+ve breast cancers [76]. To our knowledge these
studies are the ﬁrst report to address claudin 1 expression
in breast cancer in the context of ER status. We further
showed that claudin 1 positivity (as well as claudin 4) was
signiﬁcantly associated with the basal-like subtype of breast
cancers, one of the most aggressive subtypes [76]. Of note, in
a recent study by Kulka et al., 2008, it was demonstrated that
claudin 4 expression was signiﬁcantly higher in the basal-like
subtype of breast cancers [81]. Since claudin 1 is generally
considered to be a “tumor suppressor” in breast cancer, our
observations were unexpected. How can such observations
be rationalized? There are a few possible scenarios that
may explain these ﬁndings. First, it is plausible that during
tumorigenesis, not all tumor cells lose claudin 1 expression.
In line with the proposed nonlinear model of breast cancer
subtypes [18], it is possible that the cells which retain
claudin 1 expression are the cells already predetermined to
become ER−ve basal-like breast cancers. Then, in these cells,
the role of claudin 1 may be that of a tumor promoter
rather than a tumor suppressor. On the other hand, if one
considers the linear model of breast cancer subtypes [18],
tumor cells are believed to progress from ER+ve to ER−ve
as the cancer advances. Then, is the increased frequency of
claudin 1 positive tumors in the ER−ve cohort attributed
to a re-expression of claudin 1 in these tumors? Such a6 Journal of Biomedicine and Biotechnology
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Figure 3: A hypothetical model of claudin 1 expression in diﬀerent breast cancer subtypes. This model proposes that claudin 1 is a tumor
suppressor in the ER+ve subtypes of breast cancer (luminal A and B) and a tumor enhancer/facilitator in the ER−ve subtypes (basal-like,
Her2 over expressing, normal-like). Whereas a signiﬁcant association between claudin 1 and the basal-like subtype has been demonstrated,
this is yet to be determined for the Her2 over expressing and the normal-like subtypes.
concept is supported by the signiﬁcantly higher expression
of claudin 1 staining (an indicator of protein expression)
that was observed in the ER−ve tumors. Here, the tumor
suppressor function of the re-expressed claudin 1 is thus
eliminatedandnowreplacedbyatumorenhancingfunction,
thereby facilitating breast tumorigenesis. This re-expression
of claudin 1 could be attributed to a number of mitigating
factors including genetic mutation in the claudin 1 gene or
epigenetic modiﬁcation of the protein. However, sequence
analysis studies of the coding region of claudin 1 [53]i nb o t h
sporadic and hereditary breast patients failed to identify any
signiﬁcant mutation that may be responsible for altering the
claudin 1 gene expression in breast tumors. One interesting
possibility is that the higher level of the claudin 1 protein
couldbeduetoadefectiveinteractingpartnerresultinginthe
inabilityofclaudin1tobetransportedbacktothemembrane
whereitmayescapefurtherdownregulationbyotherfactors,
and therefore leading to an accumulation of claudin 1 in
the cytoplasm. The latter has recently been demonstrated
for E cadherin [82]. Furthermore, the exact combination of
claudinproteinswithinagiventissueisthoughttodetermine
the strength of the tight junction [51]. Thus, one of the
consequences of this aberrant accumulation of claudin 1
in the ER−ve invasive breast cancers may be a redeﬁnition
of the makeup of the tight junction, further undermining
the integrity of the junction and thereby further facilitating
tumor progression. Taken together, it appears that the role
of claudin 1 extends beyond that of a tumor suppressor. We
would like to propose that claudin 1 functions both as a
tumor suppressor as well as a tumor enhancer/facilitator in
breast cancer. We further propose that its tumor facilitating
role is particularly associated with the ER−ve breast cancer
subtypes (Figure 3).
Recently, a “claudin low” subtype of breast cancer has
been identiﬁed that was primarily ER−ve and exhibited low
expression of claudin 3, 4, and 7 [83]. We would further
like to propose a “claudin high” subtype that is ER–ve and
which exhibits a high expression of claudin 1 protein (and
claudin 4). This subtype would include the basal-like breast
cancersandexcludetheER+veluminalsubtypes.Theclinical
signiﬁcance of a high expression of the claudin 1 protein in
ER−ve breast cancers and its association with the basal-like
subtype may identify its potential use as a diagnostic and
prognostic indicator for a particular breast cancer subset.
7.FuturePerspectives
Mounting evidence suggests that claudin 1 has a unique role
in breast cancer and breast cancer progression. Since claudin
1 is a transmembrane protein with two large extracellular
loops, it is a potentially attractive candidate for use in
therapeutic strategies. As we begin to address the role of
claudin 1 in breast cancer progression we are left with
many unanswered questions. What is the expression level
of the claudin 1 protein in diﬀerent histological subtypes
of breast cancer? What triggers its regulation and causes
claudin 1 to switch its role at diﬀerent stages of breast
cancer progression? Why does claudin 1 accumulate in the
cytoplasm? Is there a mutation in the claudin gene or protein
in the basal-like subtype of breast cancer? Does claudin 1
work in concert with other claudins or junctional proteins
such as E cadherin? Is there cross-talk with the estrogenJournal of Biomedicine and Biotechnology 7
receptor pathway? Clearly, more detailed functional analysis
studies are warranted both in vitro and in vivo.
One can only predict that more breast cancer subtypes
will be identiﬁed in the near future and a clearer understand-
ing of the cellular and molecular changes occurring during
breast tumorigenesis will be critical for facilitating more
eﬀective patient management and directly impacting on
reducing mortality rates. Only through such understanding
will new biomarkers be identiﬁed that will report on
metastatic changes, breast cancer progression and serve
as therapeutic targets ultimately leading to speciﬁc and
individualized patient management.
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